The purpose of this study was to evaluate the effect of osteogenic differentiation of bone marrow stromal stem cells (BMSCs) on bone formation in a novel interconnected porous calcium hydroxyapatite (IP-CHA). BMSCs/IP-CHA composites, as a cell-hybrid artificial bone, were made by injecting BMSCs solution into IP-CHA scaffolds. To induce osteogenic differentiation, BMSCs/IP-CHA composites were subcultured for three, seven, 10, and 14 days. At the end of each subculture period, BMSCs/IP-CHA composites were examined by SEM and ALP staining. BMSCs/IP-CHA composites of different osteogenic groups of subculture were also placed into bone sockets in the right femur of beagle dogs. After four weeks, same placement procedure was done in the left femur. BMSCs/IP-CHA subcultured for 10 and 14 days were ALP-positive as opposed to those of three and seven days. At four weeks after placement, bone formation was superior at the 10-and 14-day subculture groups. Based on the results obtained, it was suggested that osteogenic differentiation periods with 10 and 14 days of subculture for BMSCs/IP-CHA as a cell-hybrid artificial bone were beneficial in promoting bone formation.
INTRODUCTION
Bone regeneration is of key interest in dentistry. As such, bone grafts have been used in clinical cases primarily to stimulate bone regeneration. To date, widely used bone graft materials include autogenous bone, allogeneic bone, xenogeneic bone, and some ceramics such as hydroxyapatite (HA) and tricalcium phosphate [1] [2] [3] [4] [5] [6] [7] . Currently, autogenous bone grafts are the most predictable option; however, the surgery required for harvesting the bone may cause pain and postoperative problems. In addition, the amount of bone available for use is limited and may be inadequate for some clinical cases 8, 9) .
Alternatively, demineralized freeze-dried allogeneic bone contains growth genes and maintains original osseous structure, and thus has the capacity to regenerate bone 5) . However, its use carries the risk of hepatitis or HIV infection as well as unknown possible immunoreactions, and even immunorejection 2) . Then, xenogeneic bone such as Bio-Oss ® has been shown to induce osteoconduction 4) ; however, this product has not been approved for use in Japan. Last but not least, HA and tricalcium phosphate as artificial bone have also been widely used with good biocompatibility and osteoconduction.
The crux of the matter is, bone formation is unpredictable; and in many cases, insufficient new bone is produced 10, 11) . Consequently, autogenous bone is frequently used as a graft material in clinical situations in which bone regeneration is needed. However, more recently, newer bone regeneration materials and techniques are being investigated to solve these problems.
Tissue engineering using stem cells has recently received much attention in the field of bone regeneration [11] [12] [13] [14] . It is well known that bone marrow stromal stem cells (BMSCs) contain progenitors capable of differentiation into mesenchymal lineages such as bone, cartilage, fat, and fibrous tissues 13, 14) . It has been reported that BMSCs can differentiate into osteoblasts in a culture medium that includes dexamethasone, β-glycerophosphate, and ascorbic acid 15) . Although traditional artificial bone loads cells on its surface, it is not fully functional because there is no support for the development of threedimensional structures. In contrast, many reports have documented bone formation by osteogenic differentiated BMSCs in composite scaffolds [16] [17] [18] . In the bone regeneration process, the scaffold provides a structure for cells and growth factors. Recently, a hydroxyapatite with an interconnected porous structure (IP-CHA) has been introduced. As IP-CHA has a systematic arrangement of uniform spherical pores with an interconnected network 19) , it provides a potential scaffold that allows BMSCs to readily penetrate the internal structure of hydroxyapatite to form new bone 20) . To enhance the capability of bone regeneration with this hybrid artificial bone, it is anticipated that osteogenic differentiated BMSCs will be widely used 21, 22) . However, this process has not yet been clarified in terms of the optimal osteogenic differentiation period, and therefore an in vivo examination is required.
